2-([1,2,4]Triazolo[4,3-a]quinoxalin-4-ylthio)acetic acid hydrazide (10) was used as a precursor for the syntheses of novel quinoxaline derivatives with potential anticonvulsant properties. The newly synthesized compounds have been characterized by IR, 1H?NMR, and mass spectral data followed by elemental analysis. The anticonvulsant evaluation was carried out for eleven of the synthesized compounds using metrazol induced convulsions model and phenobarbitone sodium as a standard. Among this set of tested compounds, two of them (14, and 15b) showed the best anticonvulsant activities. 1. Introduction Syntheses of quinoxalines have attracted a great deal of attention in view of their potent biological and pharmacological activities including anticonvulsant [1–4], antibacterial [5], antifungal [6], antiviral [7], antitubercular [8], antileishmanial [9], antiamoebic [10], analgesic [11], antihistaminic [12], antineoplastic [13], hypoglycemic [14], MAO-A inhibitor [15], antiarrhythmic [16], antiatherosclerotic [17], antiobese [18], and other diverse pharmacological activities. Earlier studies revealed that most of compounds derived from 1,2,4-triazoles have been found to be significant anticonvulsant [19] and tranquillizing agents [20]. Furthermore, compounds 1a–e in Figure 1 which contain [1,2,4]triazolo[4,3-a]quinoxaline moiety showed promising anticonvulsant activity [21]. Figure 1 We describe the synthesis and biological evaluation of novel [1,2,4]triazolo[4,3-a]quinoxaline derivatives expected to have anticonvulsant activity starting from 1,2-diaminobenzene and oxalic acid via quinoxaline ring build-up. 2. Results and Discussion 2.1. Chemistry The [1,2,4]triazolo[4,3-a]quinoxaline derivatives were prepared using established methodology as shown in Scheme 1. 2,3-Dichloroquinoxaline (3) was prepared by chlorination of 2,3-dihydroxyquinoxaline (2), which in turn was prepared by the condensation of the commercially available 1,2-diaminobenzene with oxalic acid in aqueous hydrochloric acid. Treatment of 3 with hydrazine hydrate yielded the corresponding 3-hydrazino compound, 4, which was subjected to ring closure to 5 by treatment with triethyl orthoformate. Reaction of 5 with thiourea in absolute ethanol afforded the isothiouronium intermediate which upon basic hydrolysis yielded [1,2,4]triazolo[4,3-a]quinoxaline-4-thiol (6). The potassium salt 7 was obtained after treatment of 6 with alcoholic KOH in a quantitative yield. Scheme 1 Reaction of the potassium salt 7 with substituted aniline in DMF gave the corresponding anilide 8a–d, and its reaction with alkyl
References
[1]
U. Erez, H. Frenk, O. Goldberg, A. Cohen, I. Vivian, and V. I. Teichberg, “Anticonvulsant properties of 3-hydroxy-2-quinoxalinecarboxylicacid, a newly found antagonist of excitatory amino acids,” European Journal of Pharmacology, vol. 110, pp. 31–39, 1985.
[2]
J. Ohmori, S. Sakamoto, H. Kubota et al., “6-(1H-imidazol-1-yl)-7-nitro-2,3 (1H,4H)-quinoxalinedione hydrochloride (YM90K) and related compounds: structure-activity relationships for the AMPA- type non-NMDA receptor,” Journal of Medicinal Chemistry, vol. 37, no. 4, pp. 467–475, 1994.
[3]
G. De Sarro, R. Gitto, E. Russo et al., “AMPA receptor antagonists as potential anticonvulsant drugs,” Current Topics in Medicinal Chemistry, vol. 5, no. 1, pp. 31–42, 2005.
[4]
G. Olayiwola, C. A. Obafemi, and F. O. Taiwo, “Synthesis and neuropharmacological activity of some quinoxalinone derivatives,” African Journal of Biotechnology, vol. 6, no. 6, pp. 777–786, 2007.
[5]
M. M. Ali, M. M. F. Ismail, M. S. A. El-Gaby, M. A. Zahran, and Y. A. Ammar, “Synthesis and antimicrobial activities of some novel quinoxalinone derivatives,” Molecules, vol. 5, no. 6, pp. 864–873, 2000.
[6]
M. M. Badran, A. A. Moneer, H. M. Refaat, and A. A. El-Malah, “Synthesis and antimicrobial activity of novel quinoxaline derivatives,” Journal of the Chinese Chemical Society, vol. 54, no. 2, pp. 469–478, 2007.
[7]
J.-P. Kleim, R. Bender, U.-M. Billhardt et al., “Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication,” Antimicrobial Agents and Chemotherapy, vol. 37, no. 8, pp. 1659–1664, 1993.
[8]
B. Zarranz, A. Jaso, I. Aldana, and A. Monge, “Synthesis and antimycobacterial activity of new quinoxaline-2-carboxamide 1,4-di-N-oxide derivatives,” Bioorganic and Medicinal Chemistry, vol. 11, no. 10, pp. 2149–2156, 2003.
[9]
J. Guillon, I. Forfar, M. Mamani-Matsuda et al., “Synthesis, analytical behaviour and biological evaluation of new 4-substituted pyrrolo[1,2-a]quinoxalines as antileishmanial agents,” Bioorganic and Medicinal Chemistry, vol. 15, no. 1, pp. 194–210, 2007.
[10]
M. Abid and A. Azam, “Synthesis, characterization and antiamoebic activity of 1-(thiazolo[4,5-b]quinoxaline-2-yl)-3-phenyl-2-pyrazoline derivatives,” Bioorganic & Medicinal Chemistry Letters, vol. 16, no. 10, pp. 2812–2816, 2006.
[11]
A. A. Abu-Hashem, M. A. Gouda, and F. A. Badria, “Synthesis of some new pyrimido[2',1':2,3]thiazolo[4,5-b]quinoxaline derivatives as anti-inflammatory and analgesic agents,” European Journal of Medicinal Chemistry, vol. 45, no. 5, pp. 1976–1981, 2010.
[12]
I. R. Ager, A. C. Barnes, G. W. Danswan et al., “Synthesis and oral antiallergic activity of carboxylic acids derived from imidazo[2,1-c][1,4]benzoxazines, imidazo[1,2-a]quinolines, imidazo[1,2-a]quinoxalines, imidazo[1,2-a]quinoxalinones, pyrrolo[1,2-a]quinoxalinones, pyrrolo[2,3-a]quinoxalinones, and imidazo[2,1-b]benzothiazoles,” Journal of Medicinal Chemistry, vol. 31, no. 6, pp. 1098–1115, 1988.
[13]
B. Solano, V. Junnotula, A. Marín et al., “Synthesis and biological evaluation of new 2-arylcarbonyl-3- trifluoromethylquinoxaline 1,4-di-N-oxide derivatives and their reduced analogues,” Journal of Medicinal Chemistry, vol. 50, no. 22, pp. 5485–5492, 2007.
[14]
M. Teng, M. D. Johnson, C. Thomas et al., “Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor,” Bioorganic and Medicinal Chemistry Letters, vol. 17, no. 19, pp. 5472–5478, 2007.
[15]
S. Y. Hassan, S. N. Khattab, A. A. Bekhit, and A. Amer, “Synthesis of 3-benzyl-2-substituted quinoxalines as novel monoamine oxidase a inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 16, no. 6, pp. 1753–1756, 2006.
[16]
K. F. M. Atta and E. S. H. El Ashry, “Synthesis of 4-(1-phenyl-1H-pyrazol-3-yl)-[1,2,4]triazolo[4,3-a] quinoxalines and their 4-halogenopyrazolyl analogs,” Journal of Heterocyclic Chemistry, vol. 48, no. 5, pp. 1216–1223, 2011.
[17]
M. R. Myers, W. He, B. Hanney et al., “Potent quinoxaline-based inhibitors of PDGF receptor tyrosine kinase activity. Part 1: SAR exploration and effective bioisosteric replacement of a phenyl substituent,” Bioorganic and Medicinal Chemistry Letters, vol. 13, no. 18, pp. 3091–3095, 2003.
[18]
G. Szabó, R. Kiss, D. Páyer-Lengyel et al., “Hit-to-lead optimization of pyrrolo[1,2-a]quinoxalines as novel cannabinoid type 1 receptor antagonists,” Bioorganic and Medicinal Chemistry Letters, vol. 19, no. 13, pp. 3471–3475, 2009.
[19]
A. Almasirad, S. A. Tabatabai, M. Faizi et al., “Synthesis and anticonvulsant activity of new 2-substituted-5-[2-(2- fluorophenoxy)phenyl]-1,3,4-oxadiazoles and 1,2,4-triazoles,” Bioorganic and Medicinal Chemistry Letters, vol. 14, no. 24, pp. 6057–6059, 2004.
[20]
J. Bicking, “Bicyclic-nitrogen-heterocyclic-compounds,” Chemical Abstracts, vol. 54, p. 8854, 1960.
[21]
S. Wagle, A. V. Adhikari, and N. S. Kumari, “Synthesis of some new 4-styryltetrazolo[1,5-a]quinoxaline and 1-substituted-4-styryl[1,2,4]triazolo[4,3-a]quinoxaline derivatives as potent anticonvulsants,” European Journal of Medicinal Chemistry, vol. 44, no. 3, pp. 1135–1143, 2009.
[22]
D. R. Romer, “Synthesis of 2,3-dichloroquinoxalines via vilsmeier reagent chlorination,” Journal of Heterocyclic Chemistry, vol. 46, no. 2, pp. 317–319, 2009.
[23]
R. Sarges, H. R. Howard, R. G. Browne, L. A. Lebel, P. A. Seymour, and B. K. Koe, “4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants,” Journal of Medicinal Chemistry, vol. 33, no. 8, pp. 2240–2254, 1990.
[24]
A. K?nnecke, R. D?rre, and E. Lippmann, “Synthesen mit Tetrazolo[1,5-a]chinoxalinen,” Zeitschrift Für Chemie, vol. 18, no. 7, pp. 257–258, 1978.
[25]
M. K. El-Said, S. M. E. Aly, F. A. Romeih, F. F. Barsoum, and A. B. Hassan, “Synthesis and pharmacological testing of some new phenothiazine derivatives,” Egyptian Journal of Pharmaceutical Sciences, vol. 32, pp. 251–261, 1991.
[26]
B. S. Furniss, A. J. Hannaford, P. W. G. Smith, and A. R. Tatchell, VOGEL'S Textbook of Practical Organic Chemistry, 5th edition, 1989.